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Background: Tissue inhibitors of metalloproteinases (TIMPs) are known to be endogenous inhibitors of matrix
metalloproteinases (MMPs). Our preliminary study showed that TIMP-2 is constitutively expressed in microglia but
significantly inhibited by lipopolysaccharide (LPS) treatment. The current study was undertaken to investigate the
role of TIMP-2 in microglia.
Methods: The expression of TIMP-2 was evaluated in the BV2 mouse microglial cell line and rat primary cultured
microglia. To investigate the role of TIMP-2, a TIMP-2 expression plasmid or small interfering RNA (siRNA) was introduced
into BV2 cells by transient transfection, and their effects on LPS-induced inflammatory reactions were examined. We
further analyzed the molecular mechanism underlying the anti-inflammatory effects of TIMP-2 by electrophoretic
mobility shift assay (EMSA), a reporter gene assay and Western blot analysis.
Results: Overexpression of TIMP-2 significantly inhibited the production of nitric oxide (NO), TNF-α, IL-1β, and reactive
oxygen species (ROS), while increasing anti-inflammatory IL-10 production. On the other hand, knockdown of
TIMP-2 augmented the production of pro-inflammatory molecules and downregulated IL-10 in LPS-stimulated
BV2 cells. The results suggest that endogenously expressed TIMP-2 plays an anti-inflammatory role. Further
mechanistic studies revealed that overexpression of TIMP-2 suppresses microglial activation via inhibition of
the activity of mitogen-activated protein kinases (MAPKs) and NF-κB with enhancement of the activity of
anti-inflammatory Nrf2 and cAMP-response element binding protein (CREB) transcription factors. TIMP-2 also
inhibited the activity and expression of LPS-induced MMP-3, −8, and −9. Finally, we demonstrated that TIMP-2
exerts a neuroprotective effect via the inhibition of microglial activation.
Conclusions: Enhancement of TIMP-2 expression may be a potential therapeutic target for neuroinflammatory
disorders.
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Microglia, resident immune cells of the central nervous
system (CNS), play an important role in brain physiology,
including sensing and regulating neuronal activities in
the intact brain [1,2]. However, microglia are activated
in response to injury and neurotoxic stimuli that can
activate inflammatory intracellular signaling pathways,
contributing to the release of various proinflammatory/* Correspondence: hskimp@ ewha.ac.kr
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unless otherwise stated.neurotoxic molecules, including nitric oxide (NO), react-
ive oxygen species (ROS), and cytokines [3-6]. Previous
studies have reported that matrix metalloproteinases
(MMPs) are also upregulated in activated microglia and
play an important role in the pathogenesis of neuroin-
flammatory disorders [7-9].
Generally, MMP activity is regulated by several mecha-
nisms, including gene transcription, proenzyme activation
and inhibition by various endogenous inhibitors such as
tissue inhibitors of metalloproteinases (TIMPs) [10,11].
TIMPs bind to active and alternative sites of activated
MMPs and inhibit MMP activity by forming a non-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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four different types of TIMPs have been characterized,
designated TIMP-1, −2, −3 and −4 [12]. TIMP-2 is con-
stitutively and widely expressed throughout the body,
whereas the expression of TIMP-1, −3, and −4 is inducible
and often exhibits tissue specificity [10,13].
TIMP-2 is a soluble, non-glycosylated, secreted protein
consisting of 194 amino acids. In the adult central nervous
system (CNS), the expression of TIMP-2 is enriched with
populations of neuronal progenitor cells, suggesting the
role of TIMP-2 in neurogenesis [10]. TIMP-2 is also
known to be associated with various neuropathological
conditions. The TIMP-2 level was reduced in the plasma
of patients with frontotemporal dementia [14]. Conversely,
TIMP-2 was significantly increased in the serum or
cerebrospinal fluid of multiple sclerosis (MS), stroke,
Alzheimer’s disease (AD), and Huntington’s disease (HD)
patients, suggesting a protective role for TIMP-2 in
these diseases [15-17]. Viral vector-mediated delivery of
TIMP-2 has been shown to inhibit the development of
experimental autoimmune encephalomyelitis or ischemic
brain injury [18,19]. In addition, our previous study has
proven that TIMP-2 has neuroprotective effects in
dopaminergic cell death [20]. Therefore, TIMP-2 has been
suggested to be a therapeutic candidate for CNS disorders,
such as MS, stroke, and Parkinson’s disease.
Although TIMP-2 is most abundantly expressed in the
adult CNS, the function of TIMP-2 in microglia has not
been demonstrated until now. We recently reported that
TIMP-2 is constitutively expressed in BV2 cells, which is
decreased after LPS treatment [8]. However, other TIMP
types, such as TIMP-1, −3, and −4, were not detected in
BV2 cells, and their expression levels were not altered
by LPS treatment. Based on these preliminary findings,
we confirmed the mRNA and protein expression of
TIMP-2 in BV2 cells and in primary microglia, and ana-
lyzed the TIMP-2 function. Using TIMP-2 overexpression
and knockdown experiments, we demonstrated, for the
first time, that TIMP-2 plays an anti-inflammatory role
in LPS-stimulated microglia. Furthermore, we analyzed
the detailed molecular mechanisms underlying the anti-
inflammatory effects of TIMP-2 in microglia.
Materials and methods
Reagents and antibodies
LPS (Escherichia coli serotype 055:B5) was obtained from
Sigma-Aldrich (St. Louis, MO, USA). All reagents used
for cell culture were purchased from Gibco BRL (Grand
Island, NY, USA). All reagents and enzymes for reverse
transcription polymerase chain reaction (RT-PCR) or
oligonucleotides for electrophoretic mobility shift assay
(EMSA) were purchased from Promega (Madison, WI,
USA). Antibodies against phospho-/total forms of mitogen-
activated protein kinases (MAPKs), β-actin or TIMP-2 weresupplied by Cell Signaling Technology (Beverley, CA, USA)
or Abcam (Cambridge, UK). All other chemicals were
obtained from Sigma-Aldrich, unless otherwise stated.
Microglial and neuronal cell cultures
The immortalized murine BV2 microglial cells and Neuro-
2a mouse neuroblastoma cell lines were grown and
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum, streptomycin (10 μg/ml) and penicillin
(10 U/ml) at 37°C. Primary microglial cells were cultured
from the cerebral cortices of 1- to 2-day-old Sprague-
Dawley rat pups as described previously [21]. All animal
experiments were approved by the Institutional Animal
Care and Use Committee at the School of Medicine, Ewha
Womans University. The purity of microglial cultures was
greater than 95%, which was confirmed by western blot
and immunocytochemisty analyses using an antibody
specific to ionized calcium-binding adapter protein-1 (IBA-
1; data not shown).
Tissue inhibitor of metalloproteinase-2 expression plasmid
The control vector (MFG/eGFP/Puro) and TIMP-2 expres-
sion vector (MFG/TIMP-2/Puro) were from Dr. Y. S. Kim
(Inje University, Seoul, Korea). The MFG/TIMP-2/Puro
vector contains the human TIMP-2 cDNA sequence under
the control of the viral 5′-LTR sequence and a selection
gene (puromycin) [22].
Transient transfection and luciferase assay
For transient overexpression of TIMP-2, BV2 cells (0.5 ×
105 cells per well in a 12-well plate) were transfected with
1 μg of plasmid DNA (control or TIMP-2 plasmid) using
the Convoy™ Platinum transfection reagent (CellTAGen,
Seoul, Korea). For the nuclear factor kappa B (NF-κB),
antioxidant response element (ARE) or cAMP response
element (CRE) reporter gene assay, BV2 cells (2 × 105
cells/well in a 12-well plate) were co-transfected with 1 μg
of the indicated reporter construct and expression vector
(control or TIMP-2 plasmid) mixed with the transfection
reagent. After 36 h, cells were treated with LPS (100 ng/ml)
and incubated for 6 h prior to harvesting cells. A luciferase
assay was performed to determine the effect of TIMP-2 on
NF-κB, ARE or CRE promoter activity.
Reverse-transcription polymerase chain reaction
To monitor gene transcript levels, BV2 cells (7.5 × 105
cells on a 6-cm dish) and rat primary microglial cells
(7 × 106 cells on a 6-cm dish) were treated with LPS, and
total RNA was extracted with TRIzol reagent (Ambion,
Austin, TX, USA). For RT-PCR, total RNA (1 μg) was
reverse transcribed in a reaction mixture containing 1 U
of RNase inhibitor, 500 ng of random primers, 3 mM
MgCl2, 0.5 mM dNTPs and 10 U of reverse transcriptase
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for PCR using GoTaq polymerase (Promega) and primers
as shown in Table 1.
Measurement of cytokine and nitrite levels
BV2 cells were treated with LPS (100 ng/ml) for 16 h,
and the supernatants were collected. The concentration
of TNF-α, IL-1β, IL-6, and IL-10 was measured by enzyme-
linked immunosorbent assay according to the manufac-
turer’s instructions (BD PharMingen, San Diego, CA,
USA). Accumulated nitrite was measured using the Griess
reagent (Promega).
Intracellular reactive oxygen species measurement
Intracellular accumulation of ROS was measured using
dichlorodihydro-fluorescein diacetate (H2DCF-DA; Sigma-
Aldrich) as described previously with modifications [23].
Briefly, microglial cells were stimulated with LPS for 16 h
and stained with 50 μM H2DCF-DA in phosphate-buffered
saline buffer for 1 h at 37°C. DCF fluorescence intensity
was measured at a 485-nm excitation and a 535-nm emis-
sion on a fluorescence plate reader (Molecular Devices,
Sunnyvale, CA, USA). Data are presented as fold changes
of control-treated values.
Knockdown of tissue inhibitor of metalloproteinase-2 by
small interfering RNA
BV2 cells (0.5 × 105 cells per well in a 12-well plate) were
transiently transfected with 100 pM of TIMP-2 small
interfering RNA (siRNA) using Ambion siPORT™ NeoFX™
transfection reagent following the manufacturer’s proto-
cols (Ambion). A scrambled control siRNA was used as a
negative control. The siRNA sequences are as follows:
TIMP-2 siRNA #1 (5′-GAAGGAGUAUCUAAUUGCA
TT-3′), TIMP-2 siRNA #2 (5′-UCCACAGACUUCAGCTable 1 Primers used in reverse-transcription polymerase cha












GAPDH GTGCTGAGTATGTCGTGGAGTCTGAAU-3′), and Control siRNA (5′-AAUCGCAUAGCG
UAUGCCGUU-3’). The cells were harvested 48 h after
siRNA transfection, and the expression levels of TIMP-2
protein were measured by western blotting.
Assays for matrix metalloproteinase-3, −8, and −9 activities
BV2 cells transfected with the TIMP-2 expression plasmid
or siRNA were treated with LPS for 24 h, and the superna-
tants were collected to measure MMP activity using the
SensoLyte™ 520 MMP assay system (AnaSpec, San Jose,
CA, USA). MMP activity measurements were performed
by continuous detection of peptide cleavage using a fluores-
cence plate reader (Molecular Devices). MMP activity units
were expressed as a change in the fluorescence intensity at
an excitation of 490 nm and an emission of 520 nm.
Electrophoretic mobility shift assay
Nuclear extracts from treated microglia were prepared
as described previously [24]. The double-stranded DNA
oligonucleotides containing NF-κB, ARE, and CRE con-
sensus sequences (Promega) were end-labeled using T4
polynucleotide kinase (New England Biolabs, Beverly,
MA, USA) in the presence of [γ-32P] ATP. Five micro-
grams of the nuclear proteins were incubated with
32P-labeled probes on ice for 30 min and were resolved
on a 5% acrylamide gel as previously described [24]. For
competitive binding assays, binding reaction reagents and
nuclear extracts were mixed with nonradioactive oligonu-
cleotides in molar excess and incubated before adding the
32P-labeled probe.
Western blot analysis
To detect MAPK activation and TIMP-2 expression, cells
lysates were prepared as previously described [24]. To de-
tect secreted TIMP-2, TIMP-2 protein in the conditionedin reaction (RT-PCR) reactions
Reverse primer (5′→ 3′) Size
CCTGGTATGAGATAGCAAAT 354 bp
TGGAACCACTCGTACTTGGGA 450 bp
G CCATTGAGGTGGAGAGCTTTCAGC 447 bp
CCAGCTTATCTGTTAGGAGA 395 bp
TA GCCTTGTAGACACCTTGGTCTT 409 bp
CTCCAGTATTTGTCCTCTAC 375 bp
CCTGCAGGAAAACTGCATCG 180 bp
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(Millipore Corp., Billerica, MA, USA). Proteins were sepa-
rated on a 12% SDS-polyacrylamide gel and transferred to
nitrocellulose membranes (GE Healthcare, Chalfont St.
Giles, Buckinghamshire, UK). After blocking of the mem-
branes with 5% skimmed milk in Tris-buffered saline with
Tween 20 (TBST), the membranes were incubated with
primary antibodies (1:1000) and then were incubated
with horseradish peroxidase-conjugated secondary anti-
bodies (1:2000 dilution in TBST; New England Biolabs,
Beverly, MA, USA), and the blots were developed using
an enhanced chemiluminescence detection kit (Thermo
Fisher Scientific, Waltham, MA, USA).
Measurement of neuronal cell viability
The control or TIMP-2 plasmid transfected BV2 cells were
treated with LPS for 24 h, and the conditioned media
were transferred to Neuro2a cells. After 24 h of incuba-
tion, the cell viability of Neuro2a cells was checked by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumA
C
Figure 1 Lipopolysaccharide (LPS) suppressed tissue inhibitor of meta
microglia. BV2 cells (A) or rat primary microglia (B) were treated with LPS
LPS treatment. The mRNA expression of TIMP-2 was measured by RT-PCR a
the top, and quantification of three independent experiments are shown a
cell lysates or conditioned medium of BV2 cells treated with LPS (100 ng/m
and were expressed as relative fold changes in comparison with control sa
and β-actin are indicated. (D) Quantification of western blot data. Values co
*P <0.05, significantly different from control samples.bromide (MTT; Sigma-Aldrich) reduction assay as pre-
viously described [21].
Statistical analysis
Unless otherwise stated, all of the experiments were per-
formed with triplicate samples and were repeated at least
three times. The data are presented as means ± the stand-
ard error of the mean (S.E.M.), and statistical comparisons
between groups were performed using one-way analysis of
variance followed by Newman-Keuls multiple comparison
test. P values less than 0.05 were deemed to indicate
statistical significance.
Results
Lipopolysaccharide inhibited tissue inhibitor of
metalloproteinase-2 expression in BV2 cells and primary
microglia
When we measured TIMP-2 mRNA expression in LPS-
treated BV2 cells at the indicated time points, TIMP-2
was constitutively expressed in resting BV2 cells, andB
D
lloproteinase (TIMP)-2 expression in BV2 cells and primary
(100 or 10 ng/ml), and total RNA was isolated at indicated times after
nd normalized to GAPDH expression. Representative gels are shown at
t the bottom panel. (C,D) Western blot analysis was performed using
l). Levels of TIMP-2 protein expression were normalized using β-actin
mples. (C) Representative western blots; molecular weights of TIMP-2
rrespond to the mean ± S.E.M. of three independent experiments.
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3 h (Figure 1A). Conversely, in primary microglia, signifi-
cant inhibition of TIMP-2 mRNA was observed after 6 h
of LPS treatment, indicating some delayed regulation
compared with that in the BV2 cell line (Figure 1B). To
confirm the changes in TIMP-2 expression at the protein
level, we performed western blot analysis in cell lysates
and conditioned media collected from LPS-treated BV2
microglia. As shown in Figure 1C, TIMP-2 protein that is
constitutively expressed in cells was time-dependently






Figure 2 Overexpression of tissue inhibitor of metalloproteinase (TIM
and reactive oxygen species (ROS), while increasing anti-inflammator
cells. (A) Control vector and TIMP-2 expression plasmid. (B) Western blot f
Effects of TIMP-2 on pro- or anti-inflammatory molecules. BV2 cells transfec
for 16 h, and the amounts of NO, TNF-α, IL-1β, IL-6, and IL-10 released into
BV2 cells transfected with TIMP-2 or control vector were treated with LPS (
inducible nitric oxide synthase (iNOS) and cytokines were determined by R
mean ± S.E.M. of three independent experiments. *P <0.05, significantly diffTIMP-2 was highest at 6 h and decreased thereafter,
probably due to its secretion into the media. Notably,
in resting microglia, TIMP-2 secretion was increased up to
48 h and was inhibited by LPS treatment (Figure 1C, D).
Overexpression of tissue inhibitor of metalloproteinase-2
suppressed the production of pro-inflammatory cytokines,
nitric oxide, and reactive oxygen species, while increasing
anti-inflammatory IL-10 production
To investigate the role of TIMP-2 in activated microglia,









P)-2 inhibited the production of nitric oxide (NO), TNF-α, IL-1β,
y IL-10 production in lipopolysaccharide (LPS)-stimulated BV2
or TIMP-2 in BV2 cells transfected with TIMP-2 or control vector. (C-H)
ted with TIMP-2 or control vector were treated with LPS (100 ng/ml)
the media, as well as the intracellular ROS level, were measured. (I)
100 ng/ml) for 6 h, and total RNA was isolated. The mRNA levels of
T-PCR. (J) Quantification of RT-PCR data. Values correspond to the
erent from the LPS + control vector group.
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that the expression of TIMP-2 was upregulated in TIMP-
2 vector-transfected cells (Figure 2B). The overexpression
of TIMP-2 reduced LPS-induced secretion of NO, TNF-α,
IL-1β without affecting the secretion of IL-6 (Figure C-F).
In addition, TIMP-2 reduced intracellular ROS produc-
tion in LPS-stimulated microglia (Figure 2G). Conversely,
TIMP-2 increased the production of the anti-inflammatory





Figure 3 Knockdown of tissue inhibitor of metalloproteinase (TIMP)-2
by small interfering RNAs (siRNAs) was confirmed by Western blotting. (B-E
oxygen species (ROS), and IL-10 production in lipopolysaccharide (LPS)-stim
LPS (100 ng/ml) for 16 h, and the amounts of NO, TNF-α, IL-10 released int
knockdown in primary microglia. (G-J) The effects of TIMP-2 knockdown on
primary microglia. Values are expressed as the means ± S.E.M. for three rep
the LPS + control siRNA group.showed that TIMP-2 suppressed LPS-induced mRNA
expression of iNOS, TNF-α, and IL-1β and upregulated
IL-10 expression (Figure 2I, J).
Knockdown of tissue inhibitor of metalloproteinase-2
expression by small interfering RNA augmented
inflammatory responses
To assess the effects of TIMP-2 in activated microglia,





aggravated inflammatory responses. (A) TIMP-2 protein reduction
) Effects of TIMP-2 knockdown on nitric oxide (NO), TNF-α, reactive
ulated BV2 cells. Cells transfected with TIMP-2 siRNA were treated with
o the media and intracellular ROS level were measured. (F) TIMP-2
pro-/anti-inflammatory molecules were confirmed in LPS-stimulated
licates using different cell cultures. *P <0.05, significantly different from
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different binding sites (Figure 3A). Next, the cells were
incubated with LPS for 16 h. We found that both siR-
NAs elevated NO, TNF-α, and ROS production, but
inhibited IL-10 production compared with the control
siRNA-treated groups (Figure 3B-E). Similar results were
observed using primary microglial cultures (Figure 3F-J).
The results indicate that endogenous TIMP-2 plays an
anti-inflammatory role in activated microglia. We found
that siRNA transfection did not significantly affect BV2
cell viability (data not shown).A
B
C
Figure 4 Tissue inhibitor of metalloproteinase (TIMP)-2 suppressed th
matrix metalloproteinase (MMP)-3, −8 and −9. (A) BV2 cells transfected
16 h, and the enzymatic activity of MMPs in cell culture supernatants were as
as a change in fluorescence intensity. Values are expressed as the means ± S.E
or control vector were treated with LPS (100 ng/ml) for 6 h, and the mRNA exp
shown in the left panel, and quantification data are shown in the right panel (n
(C) Knockdown of TIMP-2 augmented MMP activities. *P< 0.05, significantly difOverexpression of tissue inhibitor of metalloproteinase-2
suppressed the activity and expression of lipopolysaccharide-
induced matrix metalloproteinase-3, −8, and −9
TIMP-2 is known to be an endogenous inhibitor of MMPs.
Thus, we investigated whether TIMP-2 inhibits the activity
of MMP-3, −8 and −9, which have been previously reported
to be important pro-inflammatory mediators in activated
microglia [8,9]. As shown in Figure 4A, TIMP-2 overex-
pression reduced the activity of MMP-3, −8 and −9 in
LPS-stimulated BV2 cells. In addition, RT-PCR analysis
showed that TIMP-2 suppressed MMP-3, −8, and −9e activity and expression of lipopolysaccharide (LPS)-induced
with TIMP-2 or control vector were treated with LPS (100 ng/ml) for
sessed using MMP activity assay kits. MMP activity units were expressed
.M. for three independent experiments. (B) Cells transfected with TIMP-2
ression of MMPs was monitored by RT-PCR. Representative gels are
= 3). *P< 0.05, significantly different from the LPS + control vector group.
ferent from the LPS + control small interfering RNA (siRNA) group.
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knockdown of TIMP-2 elevated MMP-3, −8, and −9 activ-
ities (Figure 4C). The results suggest that TIMP-2 may
exert anti-inflammatory effects through the reduction
of MMPs .
Tissue inhibitor of metalloproteinase-2 abrogated
lipopolysaccharide-induced phosphorylation of three
types of mitogen-activated protein kinases
Next, we examined the effect of TIMP-2 on the activity
of MAP kinases, which are crucial signaling molecules
involved in inflammatory reactions and MMP gene expres-
sion. Western blot analysis revealed that overexpression of
TIMP-2 significantly inhibited LPS-induced phosphoryl-
ation of JNK, ERK, and p38 MAPK (Figure 5 A and B).
Conversely, knockdown of TIMP-2 augmented MAPK
phosphorylation (Figure 5C and D). The data suggestA B
C D
Figure 5 Mitogen-activated protein kinase (MAPK) signaling pathway
inhibitor of metalloproteinase (TIMP)-2. (A) Cells transfected with TIMP-2
for 30 min, and were subjected to immunoblot analysis using antibodies agai
of western blot data. Levels of the active forms of MAPKs were normalize
were expressed as relative fold changes compared with the MAPK levels in co
vector group. (C) Knockdown of TIMP-2 augmented MAPK phosphorylati
data. *P <0.05, significantly different from the LPS + control small interferithat MAPK signaling pathways are involved in the anti-
inflammatory effect of TIMP-2 in activated microglia.
Tissue inhibitor of metalloproteinase-2 inhibited the
DNA binding and transcriptional activities of NF-κB but
enhanced the DNA binding and transcriptional activities
of Nrf2 and cAMP-response element binding protein in
lipopolysaccharide-stimulated microglia
To explore the anti-inflammatory mechanism of TIMP-
2, we examined the effect of TIMP-2 on NF-κB, which is
an important transcription factor regulating cytokines
and MMP gene expression in microglia [25]. As shown
in Figure 6A, NF-κB DNA binding activity was reduced
in TIMP-2 overexpressed microglia compared with
that in control cells. NF-κB transcriptional activity
was assayed by co-transfecting BV2 cells with the
TIMP-2 expression plasmid and NF-κB reporter plasmids are involved in the anti-inflammatory mechanism of tissue
or control vector were treated with lipopolysaccharide (LPS) (100 ng/ml)
nst the phospho- or total forms of JNK, ERK, and p38. (B) Quantification
d with respect to the levels of the total form of MAPKs, and then
ntrol samples. *P <0.05, significantly different from the LPS + control
on in LPS-stimulated BV2 cells. (D) Quantification of Western blot




Figure 6 Tissue inhibitor of metalloproteinase (TIMP)-2 suppressed the DNA binding and transcriptional activities of NF-κB but enhanced
the DNA binding and transcriptional activities of Nrf2 and cAMP-response element binding protein (CREB). Nuclear extracts were prepared
from BV2 cells transfected with TIMP-2 or control vector after treatment with lipopolysaccharide (LPS) (100 ng/ml) for 3 h. Electrophoretic mobility shift
assay (EMSA) was performed using NF-κB (A), anti-oxidant response element (ARE) (C), or cAMP response element (CRE) (E) probe. Competition
assays indicate that the DNA-protein complex is sequence specific because the amount of complex was diminished by a molar excess of cold
oligonucleotides but not by mutant (mNF-κB) or nonspecific oligonucleotides (Sp-1 or PU1). ‘F’ indicates free probe. Transcriptional activity of
the reporter plasmids (B) (κB)3-luc, (D) ARE-luc and (F) CRE-luc in TIMP-2-overexpressed BV2 cells. Cells co-transfected with reporter plasmid
and TIMP-2 vector were treated with LPS (100 ng/ml) for 6 h, and reporter gene assay was performed. Data are reported as the means ± S.E.M.
for three separate experiments. *P <0.05, significantly different from the LPS + control vector group.
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ity assay showed that overexpression of TIMP-2 inhibited
NF-κB-mediated transcriptional activation (Figure 6B).
Next, we examined the effect of TIMP-2 on Nrf2 and
cAMP-response element binding protein (CREB), which
are key transcription factors mediating anti-inflammatory
and antioxidant functions in microglia [26]. We observed
that TIMP-2 augmented the DNA binding and tran-
scriptional activities of Nrf2 and CREB in LPS-stimu-
lated microglia (Figure 6C-F). The data suggest that
the NF-κB, Nrf2, and CREB pathways are largelyinvolved in TIMP-2-mediated anti-inflammatory effects
in microglia.
Overexpression of tissue inhibitor of metalloproteinase-2
attenuated neuronal cell death induced by activated
microglia
We examined whether TIMP-2 affects the viability of
neuronal cells by modulating microglial activation. To
determine the effect of soluble factors released from ac-
tivated BV2 cells on Neuro2a cell viability, conditioned
media from BV2 cells were transferred to Neuro2a cells.
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cells was measured using the MTT assay. We found that
the cell viability of Neuro2a was markedly improved by
overexpression of TIMP-2 compared with that in the
control vector group (Figure 7). Interestingly, we also
found that the cell viability of BV2 cells was modestly
increased in the TIMP-2-transfected group (data not
shown). Therefore, these data indicate that the cytoprotec-
tive effects of TIMP-2 were due to the reduced secretion
of proinflammatory/neurotoxic mediators from TIMP-2-
overexpressed microglia.Discussion
In the present study, we demonstrated the role of TIMP-2
in LPS-induced microglial activation. We found that
TIMP-2 is constitutively expressed in microglia, but this
expression was significantly inhibited by LPS treatment.
By utilizing TIMP-2 overexpression and knockdown, the
current study demonstrates the anti-inflammatory role of
endogenous TIMP-2 that may be attenuated by immunos-
timulatory conditions. We showed that overexpression of
TIMP-2 suppresses the production of pro-inflammatory
molecules, whereas TIMP-2 knockdown augmented
them. Moreover, TIMP-2 inhibits three types of MMPs
(MMP-3, −8 and −9) and MAPK/NF-κB signaling path-
ways. Lastly, TIMP-2 overexpression afforded neuroprotec-
tion via reduced microglial activation. Therefore, TIMP-2
is thought to be a crucial regulator of neuroinflammation.
Several studies have reported the role of TIMP-2 in the
CNS. TIMP-2 showed neuroprotective effects in an ani-
mal model of stroke by reducing the proteolytic opening
of the blood-brain barrier and subsequent intracerebral
hemorrhage [27,28]. Along with these findings, transplant-
ation of autologous bone marrow cells overexpressing
TIMP-2 reduced ischemic damage [29]. TIMP-2 was sig-
nificantly increased in the serum or cerebrospinal fluidFigure 7 Tissue inhibitor of metalloproteinase (TIMP)-2 attenuated
neuronal cell death induced by activated microglia. Neuro2a cells
were incubated with conditioned media (CM) from lipopolysaccharide
(LPS)-treated BV2 cells transfected with TIMP-2 or control vector. After
24 h of incubation, the MTT assay was performed to determine cell
viability. Values are the mean ± S.E.M. of three independent experiments.
*P <0.05, significantly different from non-LPS treated control cells.
#P <0.05, significantly different from the LPS + control vector group.(CSF) of stroke, MS, AD, or HD patients, suggesting the
protective role of TIMP-2 in neurological disorders [15-17].
Furthermore, TIMP-2 deficient mice demonstrated motor
dysfunction, including trembling prior to locomotion, ex-
cessive jumping upon moving, implying the involvement
of TIMP-2 in developmental and behavioral alterations
[30]. Because microglial activation is associated with
neuropathological conditions, the inhibition of micro-
glial activation by TIMP-2 may be one factor contributing
to TIMP-2-mediated neuroprotection.
Our group recently reported that LPS increased the
expression of MMP-3, −8, and −9 in microglia [8]. Specific
inhibition of these MMPs strongly suppressed inflam-
matory reactions induced by LPS. Thus, inhibition of
MMP-3, −8, or −9 inhibited the expression of iNOS and
proinflammatory cytokines and also suppressed MAPK
and NF-κB activities, as well as ROS production [8]. We
demonstrated that MMP-3, −8, −9 play pro-inflammatory
roles by activating protease activated receptor-1 on the
surface of microglia and/or by cleavage/activation of
proTNF-α [9]. In the present study, we found that TIMP-
2 overexpression suppressed proinflammatory signaling
in a manner similar to that of MMP inhibitors. The data
suggest that the anti-inflammatory effect of TIMP-2 is the
result of a mechanism dependent on the MMP pathway.
Activated microglia release inflammatory cytokines and
neurotoxic factors, as well as amplify the inflammatory
response in an autocrine or paracrine manner. Add-
itionally, released toxic factors from activated microglia
cause neuronal death, which contributes to neurode-
generation in a positive feedback loop [3-6]. Our find-
ings suggest that the neuroprotective effects of TIMP-2
were due to the reduced secretion of proinflammatory/
neurotoxic mediators from microglia. Thus, TIMP-2 may
likely control neurotoxicity through the modulation of
microglial activation.Conclusions
The present study demonstrated that TIMP-2 exerts anti-
inflammatory effects through the reduction of MMPs and
pro-inflammatory molecules. Therefore, the endogenous
system of TIMP-2, which can modulate the abnormal ex-
pression of MMPs and the concomitant inflammatory
response, may be a promising target for the treatment
of various neuroinflammatory disorders.Abbreviations
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